MediGene: European Patent Office decides to grant new European Patent for Veregen
Up to now, patent protection for Veregen® was limited to the application of tea catechins for the production of a drug for the treatment of tissue infected by human papilloma viruses. This comprehensive patent was filed by the Cancer Institute Chinese Academy of Medical Sciences and the Japanese company Mitsui Norin, and licensed exclusively by MediGene.
The new European patent (EP 1448186) affords additional patent protection through the end of 2022, and also has the possibility of term extension.
Dr. Peter Heinrich, MediGene's Chief Executive Officer, commented: "With this additional patent Veregen® ointment is now protected by two independent families of patents. We are now fully prepared for the next steps with Veregen®, notably its planned European commercialization."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.